The maker of Ozempic is cutting the price of the drug nearly in half for some patients. Novo Nordisk had already cut the price of Wegovy, a medication with the same active ingredient that's approved for weight loss.

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why.

Novo Nordisk launches a new cash-pay option for a leading diabetes drug, changing affordability dynamics for uninsured patients across the U.S.